HSP90AA1 and neoplasm: It has been shown that a combination of the Hsp90 inhibitor SNX-5422 and trastuzumab (herceptin), a monoclonal antibody that blocks the Her-2 receptor, led to a synergistic regression of tumor growth in a xenograft model of human breast cancer [146].